Medine.co.uk

Galloways Cough Expectorant

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Galloway’s Cough Expectorant

2.    QUALITATIVE AND QUANTITATIVE COMPOSITION

Guaifenesin 1.50% w/v For excipients see 6.1.

3.    PHARMACEUTICAL FORM

Syrup

4    CLINICAL PARTICULARS

4.1.    Therapeutic indications

For the relief of chesty coughs, hoarseness and sore throats associated with upper respiratory tract infections.

4.2 Posology and method of administration

Route of administration: oral.

Adults and the elderly: 10 ml maximum every 2-3 hours.

Children 3-12 years: 5 ml maximum every 2-3 hours.

4.3.    Contraindications

Galloway’s Cough Expectorant is contraindicated in individuals with known hypersensitivity to the product or any of its components.

4.4 Special warnings and precautions for use

Not more than twelve doses should be given in any 24 hours. Do not exceed the stated dose.

Do not take with any other cough and cold medicine.

Consult a pharmacist or other healthcare professional before use in children under 6 years.

4.5.    Interactions with other medicinal products and other forms of interaction

None known.

4.6.    Pregnancy and lactation

No known restrictions.

4.7.    Effects on ability to drive and use machines

None known.

4.8.    Undesirable effects

None known.

4.9.    Overdose

Excessive overdose will cause self-limiting vomiting.

5 PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Guaifenesin is reported to have effects on lowering the viscosity of tenacious sputum.

5.2. Pharmacokinetic properties

Not applicable.

5.3. Preclinical safety data

No pre-clinical safety problems have been reported.

6 PHARMACEUTICAL PARTICULARS

6.1. List of excipients

Invert Sugar

Sodium Benzoate (E211) Sodium Citrate Acetic Acid (80% pure) Citric Acid Monohydrate Ethanol 96%

Menthol

Aniseed Flavour FP682/A Cough Flavour 580.107/T Caramel 15712 (E150) Filtered tap water

6.2. Incompatibilities

None known.

6.3. Shelf life

24 months.

6.4. Special precautions for storage

None

Nature and contents of container

6.5


75 ml bottle: R.O.P.P. Aluminium cap or plastic cap. 150 ml bottle: R.O.P.P. Aluminium cap or plastic cap. 300 ml bottle: R.O.P.P. Aluminium cap or plastic cap.

6.6. Instructions for use, handling, (and disposal)

None

7. MARKETING AUTHORISATION HOLDER

Omega Pharma Ltd. 1st Floor 32 Vauxhall Bridge Road LONDON, SW1V 2SA United Kingdom

8. MARKETING AUTHORISATION NUMBER

PL 02855/0027

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

16/11/2004

10 DATE OF REVISION OF THE TEXT

30/09/2014